Abstract
Thalassemia, one of the most common genetic disorders, is considered to be a global problem. Several millions of the patients suffer from severe thalassemic diseases. Stem cell transplantation is currently the only curative therapy. Bone marrow transplantation offers a high probability of cure when performed in young children. There is a higher risk as the patient becomes older, especially the high incidence of graft rejection. Modified conditioning regimens have been developed to overcome graft rejection in patients with class III or full blown manifestations. The alternative use of stem cell from cord blood makes possible earlier transplant with better chance of cure, although the engraftment is slower compared to bone marrow transplantation. More experiences with regard to stem cell transplantation in adult patients, the use of stem cell transplantation from related donors as well as matched unrelated donors are necessary.
Similar content being viewed by others
References
Chernoff AI. The distribution of the thalassemia gene. A historical review.Blood. 1959;14:899.
Weatherall DJ. Thalassemia in the next millennium.Ann NY Acad Sci. 1998;850:1–9.
Wasi P. Haemoglobinopathies including thalassemia. Part 1.Tropical Asia. Clin Haematol. 1981;10:702–729.
Fucharoen S, Winichagoon P. Clinical and hematologic aspects of hemoglobin E β-thalassemia.Cur Opin Hematol. 2000;7:106–112.
Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia.N Engl J Med. 1990;322:417–421.
Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients.Blood. 1996;87:2082–2088.
Angelucci E, Lucarelli G. Bone marrow transplantation in β-thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL (eds). Disorders of Hemoglobin: Geneties, Pathophysiology and Clinical Management, pp 1052–1072. Cambridge: Cambridge University Press, 2001.
Issaragrisil S, Suvatte V, Visudhisakchai S, et al. Bone marrow and cord blood stem cell transplantation for thalassemia in Thailand.Bone Marrow Transplant. 1997;19(Suppl 2):54–56.
Sodani P, Gaziev D, Erer B, et al. New preparative regimen for bone marrow transplantation in Class 3 young and adult thalassemic patients.Bone Marrow Transplant. 2002;29(Suppl 2).
Barbanti I, Muretto P. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassemia.Brit J Haematol. 1995;89:868–873.
Angelucci E, Ripalti M, Baronchiani D, et al Phlebotomy to reduce iron overload in patients cured of thalassemia by marrow transplantation.Bone Marrow Transplant. 1997;19 (Suppl 2):123–125.
Gaziev J, Galimberti M, Giardini C, et al. Growth in children after bone marrow transplantation for thalassemia.Bone Marrow Transplant. 1993;12(Suppl 3):100–101.
de Sanctis V, Galimberti M, Lucarelli G, et al. Growth and development in ex-thalassemia patients.Bone Marrow Transplant. 1997;19(Suppl 2):48–53.
de Sanctis V, Galimberti M, Lucarelli G, et al. Gonadal function after allogeneic bone marrow transplantation for thalassemia.Arch Dis Child. 1991;66:517–521.
de Simone M, Oloioso P, di Bartolomeo P, et al. Growth and endocrine function following bone marrow transplantation for thalassemia.Bone Marrow Transplant. 1995;15:227–233.
Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemia patients.Blood. 1999;93:1164–1167.
Gaziev D, Galimberti M, Luccuelli G, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants.Bone Marrow Transplant. 2000;25:815–821.
La Nasa G, Giardini C, Locatelli F, et al. Unrelated donor bone marrow transplantation for thalassemia (preliminary report).Blood. 2000;96(Suppl 1):414a.
Issaragrisil S, Visuthisakchai S, Suvatte V, et al. Transplantation of cord blood stem celll into a patient with severe thalassemia.N Engl J Med. 1995;332:367–369.
Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91:756–763.
Aker M, Kapelushnik J, Pugatsch T, et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major.J Ped Hematol Oncol. 1998;20:145–148.
Author information
Authors and Affiliations
About this article
Cite this article
Issaragrisil, S. Stem cell transplantation for thalassemia. Int J Hematol 76 (Suppl 1), 307–309 (2002). https://doi.org/10.1007/BF03165269
Issue Date:
DOI: https://doi.org/10.1007/BF03165269